Journal article
Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings
TY Wong, J Sun, R Kawasaki, P Ruamviboonsuk, N Gupta, VC Lansingh, M Maia, W Mathenge, S Moreker, MMK Muqit, S Resnikoff, J Verdaguer, P Zhao, F Ferris, LP Aiello, HR Taylor
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2018
Abstract
Diabetes mellitus (DM) is a global epidemic and affects populations in both developing and developed countries, with differing health care and resource levels. Diabetic retinopathy (DR) is a major complication of DM and a leading cause of vision loss in working middle-aged adults. Vision loss from DR can be prevented with broad-level public health strategies, but these need to be tailored to a country's and population's resource setting. Designing DR screening programs, with appropriate and timely referral to facilities with trained eye care professionals, and using cost-effective treatment for vision-threatening levels of DR can prevent vision loss. The International Council of Ophthalmolog..
View full abstractGrants
Funding Acknowledgements
The author(s) have made the following disclosure(s): T.Y.W.: Financial support - the STaR Award, National Medical Research Council, Singapore, which funded the drafting and preparation of the manuscript.r J.S.: Financial support - Genentech, Eleven Biotherapeutics, Vindico Medical Education, Kalvista, Merck, Allergan, Kowa, Novartis, Regeneron, Bayer; Nonfinancial support - Optovue, Boston Micromachines, Genentech, Novartis, Regeneron, Novo Nordisk, Adaptive Sensory Technologies.r R.K.: Financial support and Advisory board - Bayer, Novartis, Senju, Roche, Predictive Analytics Group Pty. Ltd, Office Future Co.; Financial support - Bayer, Novartis, Senju.r P.R.: Financial support - Novartis, Bayer, Allergan.